Difference between revisions of "Hepatoblastoma"

From HemOnc.org - A Hematology Oncology Wiki
Jump to navigation Jump to search
m
Line 10: Line 10:
 
|}
 
|}
 
{{TOC limit|limit=3}}
 
{{TOC limit|limit=3}}
−
 
 
=Adjuvant therapy=
 
=Adjuvant therapy=
 
==Cisplatin & Fluorouracil (CF) & Vincristine {{#subobject:50f9da|Regimen=1}}==
 
==Cisplatin & Fluorouracil (CF) & Vincristine {{#subobject:50f9da|Regimen=1}}==
−
 
+
<div class="toccolours" style="background-color:#eeeeee">
 
===Regimen===
 
===Regimen===
 
{| class="wikitable sortable" style="width: 100%; text-align:center;"  
 
{| class="wikitable sortable" style="width: 100%; text-align:center;"  
Line 22: Line 21:
 
!style="width: 20%"|[[Levels_of_Evidence#Comparative_efficacy|Comparative Efficacy]]
 
!style="width: 20%"|[[Levels_of_Evidence#Comparative_efficacy|Comparative Efficacy]]
 
|-
 
|-
−
|[https://doi.org/10.1016/S1470-2045(18)30895-7 Katzenstein et al. 2019 (AHEP0731)]
+
|[https://www.ncbi.nlm.nih.gov/pmc/articles/pmc6499702/ Katzenstein et al. 2019 (AHEP0731)]
 
|2010-2014
 
|2010-2014
 
| style="background-color:#1a9851" |Phase 3 (E-esc)
 
| style="background-color:#1a9851" |Phase 3 (E-esc)
Line 30: Line 29:
 
|}
 
|}
 
''For stage 1 or 2 '''hepatoblastoma''' without 100% pure fetal stage I or small-cell undifferentiated histology with complete resection at diagnosis and no history of prior chemotherapy or liver directed therapy. Eligible patients include: patients< 21 years old, elevated serum α-fetoprotein level (>100 ng/mL), at least 50% Karnofsky (patients >16 years) or Lansky (patients ≤16 years) performance status.''
 
''For stage 1 or 2 '''hepatoblastoma''' without 100% pure fetal stage I or small-cell undifferentiated histology with complete resection at diagnosis and no history of prior chemotherapy or liver directed therapy. Eligible patients include: patients< 21 years old, elevated serum α-fetoprotein level (>100 ng/mL), at least 50% Karnofsky (patients >16 years) or Lansky (patients ≤16 years) performance status.''
−
 
+
<div class="toccolours" style="background-color:#cbd5e8">
 
====Preceding treatment====
 
====Preceding treatment====
−
 
 
*Curative [[Surgery#Hepatobiliary_cancer_surgery|surgical resection]]
 
*Curative [[Surgery#Hepatobiliary_cancer_surgery|surgical resection]]
−
 
+
</div>
 +
<div class="toccolours" style="background-color:#b3e2cd">
 
====Chemotherapy====
 
====Chemotherapy====
−
 
 
*[[Cisplatin (Platinol)]] by the following weight-based criteria:
 
*[[Cisplatin (Platinol)]] by the following weight-based criteria:
 
**Less than 10 kg: 3.3 mg/kg IV over 6 hours once on day 1
 
**Less than 10 kg: 3.3 mg/kg IV over 6 hours once on day 1
Line 46: Line 44:
 
**Less than 10 kg: 0.05 mg/kg IV once per day on days 2, 9, 16
 
**Less than 10 kg: 0.05 mg/kg IV once per day on days 2, 9, 16
 
**10 kg or more: 1.5 mg/m<sup>2</sup> (maximum dose of 2 mg) IV once per day on days 2, 9, 16
 
**10 kg or more: 1.5 mg/m<sup>2</sup> (maximum dose of 2 mg) IV once per day on days 2, 9, 16
−
 
 
'''21-day cycle for 1 cycle (to be given within 42 days of resection)'''
 
'''21-day cycle for 1 cycle (to be given within 42 days of resection)'''
−
 
+
</div></div>
 
===References===
 
===References===
−
 
+
#'''AHEP0731:''' Katzenstein HM, Langham MR, Malogolowkin MH, Krailo MD, Towbin AJ, McCarville MB, Finegold MJ, Ranganathan S, Dunn S, McGahren ED, Tiao GM, O'Neill AF, Qayed M, Furman WL, Xia C, Rodriguez-Galindo C, Meyers RL; Children's Oncology Group. Minimal adjuvant chemotherapy for children with hepatoblastoma resected at diagnosis (AHEP0731): a Children's Oncology Group, multicentre, phase 3 trial. Lancet Oncology. 2019 May 1. 20(5) 719-727. Epub 2019 Apr 8. [https://doi.org/10.1016/S1470-2045(18)30895-7 link to original article] [https://www.ncbi.nlm.nih.gov/pmc/articles/pmc6499702/ link to PMC article] [https://pubmed.ncbi.nlm.nih.gov/30975630/ PubMed] NCT00980460
−
#'''AHEP0731:''' Katzenstein HM, Langham MR, Malogolowkin MH, Krailo MD, Towbin AJ, McCarville MB, Finegold MJ, Ranganathan S, Dunn S, McGahren ED, Tiao GM, O'Neill AF, Qayed M, Furman WL, Xia C, Rodriguez-Galindo C, Meyers RL; Children's Oncology Group. Minimal adjuvant chemotherapy for children with hepatoblastoma resected at diagnosis (AHEP0731): a Children's Oncology Group, multicentre, phase 3 trial. Lancet Oncology. 2019 May 1. 20(5) 719-727. Epub 2019 Apr 8. [https://doi.org/10.1016/S1470-2045(18)30895-7 link to original article] [https://pubmed.ncbi.nlm.nih.gov/30975630/ PubMed] NCT00980460
 
−
 
 
 
=All lines of therapy=
 
=All lines of therapy=
 
==Cisplatin monotherapy {{#subobject:ea894c|Regimen=1}}==
 
==Cisplatin monotherapy {{#subobject:ea894c|Regimen=1}}==
−
 
+
<div class="toccolours" style="background-color:#eeeeee">
 
===Regimen {{#subobject:9134b2|Variant=1}}===
 
===Regimen {{#subobject:9134b2|Variant=1}}===
 
{| class="wikitable sortable" style="width: 100%; text-align:center;"  
 
{| class="wikitable sortable" style="width: 100%; text-align:center;"  
Line 80: Line 75:
 
|-
 
|-
 
|}
 
|}
 +
<div class="toccolours" style="background-color:#b3e2cd">
 
====Chemotherapy====
 
====Chemotherapy====
 
*[[Cisplatin (Platinol)]]
 
*[[Cisplatin (Platinol)]]
−
 
+
</div></div>
 
===References===
 
===References===
 
# '''SIOPEL 3:''' Perilongo G, Maibach R, Shafford E, Brugieres L, Brock P, Morland B, de Camargo B, Zsiros J, Roebuck D, Zimmermann A, Aronson D, Childs M, Widing E, Laithier V, Plaschkes J, Pritchard J, Scopinaro M, MacKinlay G, Czauderna P. Cisplatin versus cisplatin plus doxorubicin for standard-risk hepatoblastoma. N Engl J Med. 2009 Oct 22;361(17):1662-70. [https://doi.org/10.1056/NEJMoa0810613 link to original article] [https://pubmed.ncbi.nlm.nih.gov/19846851 PubMed] NCT00003912
 
# '''SIOPEL 3:''' Perilongo G, Maibach R, Shafford E, Brugieres L, Brock P, Morland B, de Camargo B, Zsiros J, Roebuck D, Zimmermann A, Aronson D, Childs M, Widing E, Laithier V, Plaschkes J, Pritchard J, Scopinaro M, MacKinlay G, Czauderna P. Cisplatin versus cisplatin plus doxorubicin for standard-risk hepatoblastoma. N Engl J Med. 2009 Oct 22;361(17):1662-70. [https://doi.org/10.1056/NEJMoa0810613 link to original article] [https://pubmed.ncbi.nlm.nih.gov/19846851 PubMed] NCT00003912
 
# '''SIOPEL 6:''' Brock PR, Maibach R, Childs M, Rajput K, Roebuck D, Sullivan MJ, Laithier V, Ronghe M, Dall'Igna P, Hiyama E, Brichard B, Skeen J, Mateos ME, Capra M, Rangaswami AA, Ansari M, Rechnitzer C, Veal GJ, Covezzoli A, Brugières L, Perilongo G, Czauderna P, Morland B, Neuwelt EA. Sodium Thiosulfate for Protection from Cisplatin-Induced Hearing Loss. N Engl J Med. 2018 Jun 21;378(25):2376-2385. [https://doi.org/10.1056/nejmoa1801109 link to original article] [https://www.ncbi.nlm.nih.gov/pmc/articles/pmc6117111/ link to PMC article] [https://pubmed.ncbi.nlm.nih.gov/29924955/ PubMed] NCT00652132
 
# '''SIOPEL 6:''' Brock PR, Maibach R, Childs M, Rajput K, Roebuck D, Sullivan MJ, Laithier V, Ronghe M, Dall'Igna P, Hiyama E, Brichard B, Skeen J, Mateos ME, Capra M, Rangaswami AA, Ansari M, Rechnitzer C, Veal GJ, Covezzoli A, Brugières L, Perilongo G, Czauderna P, Morland B, Neuwelt EA. Sodium Thiosulfate for Protection from Cisplatin-Induced Hearing Loss. N Engl J Med. 2018 Jun 21;378(25):2376-2385. [https://doi.org/10.1056/nejmoa1801109 link to original article] [https://www.ncbi.nlm.nih.gov/pmc/articles/pmc6117111/ link to PMC article] [https://pubmed.ncbi.nlm.nih.gov/29924955/ PubMed] NCT00652132
−
 
 
==Cisplatin & Doxorubicin {{#subobject:7bb59c|Regimen=1}}==
 
==Cisplatin & Doxorubicin {{#subobject:7bb59c|Regimen=1}}==
−
 
 
PLADO: '''<u>PLA</u>'''tinol (Cisplatin) & '''<u>DO</u>'''xorubicin
 
PLADO: '''<u>PLA</u>'''tinol (Cisplatin) & '''<u>DO</u>'''xorubicin
 +
<div class="toccolours" style="background-color:#eeeeee">
 
===Regimen {{#subobject:c48515|Variant=1}}===
 
===Regimen {{#subobject:c48515|Variant=1}}===
 
{| class="wikitable sortable" style="width: 100%; text-align:center;"  
 
{| class="wikitable sortable" style="width: 100%; text-align:center;"  
Line 121: Line 116:
 
|-
 
|-
 
|}
 
|}
 +
<div class="toccolours" style="background-color:#b3e2cd">
 
====Chemotherapy====
 
====Chemotherapy====
 
*[[Cisplatin (Platinol)]]
 
*[[Cisplatin (Platinol)]]
 
*[[Doxorubicin (Adriamycin)]]
 
*[[Doxorubicin (Adriamycin)]]
−
 
+
</div></div>
 
===References===
 
===References===
 
# Ortega JA, Douglass EC, Feusner JH, Reynolds M, Quinn JJ, Finegold MJ, Haas JE, King DR, Liu-Mares W, Sensel MG, Krailo MD; Children's Cancer Group; Pediatric Oncology Group. Randomized comparison of cisplatin/vincristine/fluorouracil and cisplatin/continuous infusion doxorubicin for treatment of pediatric hepatoblastoma: a report from the Children's Cancer Group and the Pediatric Oncology Group. J Clin Oncol. 2000 Jul;18(14):2665-75. [https://doi.org/10.1200/JCO.2000.18.14.2665 link to original article] [https://pubmed.ncbi.nlm.nih.gov/10894865 PubMed]
 
# Ortega JA, Douglass EC, Feusner JH, Reynolds M, Quinn JJ, Finegold MJ, Haas JE, King DR, Liu-Mares W, Sensel MG, Krailo MD; Children's Cancer Group; Pediatric Oncology Group. Randomized comparison of cisplatin/vincristine/fluorouracil and cisplatin/continuous infusion doxorubicin for treatment of pediatric hepatoblastoma: a report from the Children's Cancer Group and the Pediatric Oncology Group. J Clin Oncol. 2000 Jul;18(14):2665-75. [https://doi.org/10.1200/JCO.2000.18.14.2665 link to original article] [https://pubmed.ncbi.nlm.nih.gov/10894865 PubMed]
 
# '''SIOPEL 1:''' Pritchard J, Brown J, Shafford E, Perilongo G, Brock P, Dicks-Mireaux C, Keeling J, Phillips A, Vos A, Plaschkes J. Cisplatin, doxorubicin, and delayed surgery for childhood hepatoblastoma: a successful approach--results of the first prospective study of the International Society of Pediatric Oncology. J Clin Oncol. 2000 Nov 15;18(22):3819-28. [https://doi.org/10.1200/jco.2000.18.22.3819 link to original article] [https://pubmed.ncbi.nlm.nih.gov/11078495 PubMed]  
 
# '''SIOPEL 1:''' Pritchard J, Brown J, Shafford E, Perilongo G, Brock P, Dicks-Mireaux C, Keeling J, Phillips A, Vos A, Plaschkes J. Cisplatin, doxorubicin, and delayed surgery for childhood hepatoblastoma: a successful approach--results of the first prospective study of the International Society of Pediatric Oncology. J Clin Oncol. 2000 Nov 15;18(22):3819-28. [https://doi.org/10.1200/jco.2000.18.22.3819 link to original article] [https://pubmed.ncbi.nlm.nih.gov/11078495 PubMed]  
 
# '''SIOPEL 3:''' Perilongo G, Maibach R, Shafford E, Brugieres L, Brock P, Morland B, de Camargo B, Zsiros J, Roebuck D, Zimmermann A, Aronson D, Childs M, Widing E, Laithier V, Plaschkes J, Pritchard J, Scopinaro M, MacKinlay G, Czauderna P. Cisplatin versus cisplatin plus doxorubicin for standard-risk hepatoblastoma. N Engl J Med. 2009 Oct 22;361(17):1662-70. [https://doi.org/10.1056/NEJMoa0810613 link to original article] [https://pubmed.ncbi.nlm.nih.gov/19846851 PubMed] NCT00003912
 
# '''SIOPEL 3:''' Perilongo G, Maibach R, Shafford E, Brugieres L, Brock P, Morland B, de Camargo B, Zsiros J, Roebuck D, Zimmermann A, Aronson D, Childs M, Widing E, Laithier V, Plaschkes J, Pritchard J, Scopinaro M, MacKinlay G, Czauderna P. Cisplatin versus cisplatin plus doxorubicin for standard-risk hepatoblastoma. N Engl J Med. 2009 Oct 22;361(17):1662-70. [https://doi.org/10.1056/NEJMoa0810613 link to original article] [https://pubmed.ncbi.nlm.nih.gov/19846851 PubMed] NCT00003912
−
 
 
[[Category:Hepatoblastoma regimens]]
 
[[Category:Hepatoblastoma regimens]]
 
[[Category:Disease-specific pages]]
 
[[Category:Disease-specific pages]]
 
[[Category:Pediatric solid tumors]]
 
[[Category:Pediatric solid tumors]]

Revision as of 13:28, 25 February 2023

Back to Top

Section editor transclusions

7 regimens on this page
7 variants on this page


Adjuvant therapy

Cisplatin & Fluorouracil (CF) & Vincristine

Regimen

Study Years of enrollment Evidence Comparator Comparative Efficacy
Katzenstein et al. 2019 (AHEP0731) 2010-2014 Phase 3 (E-esc) Observation Seems to have superior EFS

For stage 1 or 2 hepatoblastoma without 100% pure fetal stage I or small-cell undifferentiated histology with complete resection at diagnosis and no history of prior chemotherapy or liver directed therapy. Eligible patients include: patients< 21 years old, elevated serum α-fetoprotein level (>100 ng/mL), at least 50% Karnofsky (patients >16 years) or Lansky (patients ≤16 years) performance status.

Preceding treatment

Chemotherapy

  • Cisplatin (Platinol) by the following weight-based criteria:
    • Less than 10 kg: 3.3 mg/kg IV over 6 hours once on day 1
    • 10 kg or more: 100 mg/m2 over 6 hours once on day 1
  • Fluorouracil by the following weight-based criteria:
    • Less than 10 kg: 20 mg/kg IV once on day 2
    • 10 kg or more: 600 mg/m2 IV once on day 2
  • Vincristine by the following weight-based criteria:
    • Less than 10 kg: 0.05 mg/kg IV once per day on days 2, 9, 16
    • 10 kg or more: 1.5 mg/m2 (maximum dose of 2 mg) IV once per day on days 2, 9, 16

21-day cycle for 1 cycle (to be given within 42 days of resection)

References

  1. AHEP0731: Katzenstein HM, Langham MR, Malogolowkin MH, Krailo MD, Towbin AJ, McCarville MB, Finegold MJ, Ranganathan S, Dunn S, McGahren ED, Tiao GM, O'Neill AF, Qayed M, Furman WL, Xia C, Rodriguez-Galindo C, Meyers RL; Children's Oncology Group. Minimal adjuvant chemotherapy for children with hepatoblastoma resected at diagnosis (AHEP0731): a Children's Oncology Group, multicentre, phase 3 trial. Lancet Oncology. 2019 May 1. 20(5) 719-727. Epub 2019 Apr 8. link to original article link to PMC article PubMed NCT00980460

All lines of therapy

Cisplatin monotherapy

Regimen

Study Years of enrollment Evidence Comparator Comparative Efficacy Comparative Toxicity
Perilongo et al. 2009 (SIOPEL 3) 1998-2006 Phase 3 (E-de-esc) Cisplatin & Doxorubicin Non-inferior complete resection rate
Brock et al. 2018 (SIOPEL 6) 2007-2014 Phase 3 (C) Cisplatin & Sodium thiosulfate More hearing loss

Chemotherapy

References

  1. SIOPEL 3: Perilongo G, Maibach R, Shafford E, Brugieres L, Brock P, Morland B, de Camargo B, Zsiros J, Roebuck D, Zimmermann A, Aronson D, Childs M, Widing E, Laithier V, Plaschkes J, Pritchard J, Scopinaro M, MacKinlay G, Czauderna P. Cisplatin versus cisplatin plus doxorubicin for standard-risk hepatoblastoma. N Engl J Med. 2009 Oct 22;361(17):1662-70. link to original article PubMed NCT00003912
  2. SIOPEL 6: Brock PR, Maibach R, Childs M, Rajput K, Roebuck D, Sullivan MJ, Laithier V, Ronghe M, Dall'Igna P, Hiyama E, Brichard B, Skeen J, Mateos ME, Capra M, Rangaswami AA, Ansari M, Rechnitzer C, Veal GJ, Covezzoli A, Brugières L, Perilongo G, Czauderna P, Morland B, Neuwelt EA. Sodium Thiosulfate for Protection from Cisplatin-Induced Hearing Loss. N Engl J Med. 2018 Jun 21;378(25):2376-2385. link to original article link to PMC article PubMed NCT00652132

Cisplatin & Doxorubicin

PLADO: PLAtinol (Cisplatin) & DOxorubicin

Regimen

Study Years of enrollment Evidence Comparator Comparative Efficacy Comparative Toxicity
Ortega et al. 2000 1989-1992 Phase 3 (E-switch-ic) CF & Vincristine More toxic
Pritchard et al. 2000 (SIOPEL 1) 1990-1994 Non-randomized
Perilongo et al. 2009 (SIOPEL 3) 1998-2006 Phase 3 (C) Cisplatin Non-inferior complete resection rate

Chemotherapy

References

  1. Ortega JA, Douglass EC, Feusner JH, Reynolds M, Quinn JJ, Finegold MJ, Haas JE, King DR, Liu-Mares W, Sensel MG, Krailo MD; Children's Cancer Group; Pediatric Oncology Group. Randomized comparison of cisplatin/vincristine/fluorouracil and cisplatin/continuous infusion doxorubicin for treatment of pediatric hepatoblastoma: a report from the Children's Cancer Group and the Pediatric Oncology Group. J Clin Oncol. 2000 Jul;18(14):2665-75. link to original article PubMed
  2. SIOPEL 1: Pritchard J, Brown J, Shafford E, Perilongo G, Brock P, Dicks-Mireaux C, Keeling J, Phillips A, Vos A, Plaschkes J. Cisplatin, doxorubicin, and delayed surgery for childhood hepatoblastoma: a successful approach--results of the first prospective study of the International Society of Pediatric Oncology. J Clin Oncol. 2000 Nov 15;18(22):3819-28. link to original article PubMed
  3. SIOPEL 3: Perilongo G, Maibach R, Shafford E, Brugieres L, Brock P, Morland B, de Camargo B, Zsiros J, Roebuck D, Zimmermann A, Aronson D, Childs M, Widing E, Laithier V, Plaschkes J, Pritchard J, Scopinaro M, MacKinlay G, Czauderna P. Cisplatin versus cisplatin plus doxorubicin for standard-risk hepatoblastoma. N Engl J Med. 2009 Oct 22;361(17):1662-70. link to original article PubMed NCT00003912
Retrieved from "https://hemonc.org/w/index.php?title=Hepatoblastoma&oldid=66443"